Skip to main content

Asuragen Licenses RNA, DNA Standards Technology to BD for MDx Development

NEW YORK (GenomeWeb News) – Asuragen today announced it has granted Becton Dickinson the rights to incorporate its Armored RNA technology into BD's in vitro molecular diagnostic products.

Asuragen will develop and supply reagents for BD Diagnostics in Asuragen's cGMP manufacturing facility under the terms of the deal. Other details of the non-exclusive worldwide agreement were not disclosed.

Armored RNA was jointly invented and developed by Asuragen and Cenetron Diagnostics to create RNA and DNA standards for molecular diagnostic assays. The technology has been incorporated into most HIV and HCV commercially available diagnostic assays that measure viral load, Austin, Texas-based Asuragen said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.